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Abstract: Statins provide a very effective approach in reducing plasma cholesterol levels and 
cardiovascular risk. However, the proportion of patients who fail to achieve desirable plasma 
lipid levels ranges from 16%–53%, worldwide. This percentage reaches up to 80% in patients 
with familial hypercholesterolemia. Additionally, many patients are unable to tolerate statins, 
particularly at the highest approved dose level. New treatments that aggressively reduce lipid 
levels in patients with severe hypercholesterolemia, or those unable to reach their lipid targets, 
are therefore required. The most promising approaches in this context, such as inhibitors of the 
synthesis of apolipoprotein B (apoB) containing lipoproteins (apoB silencing or microsomal 
triglyceride transfer protein [MTP] inhibition) or proprotein convertase subtilisin/kexin type 
9 (PCSK9) blockers, all decrease low-density lipoprotein (LDL) extensively. Increasing low 
levels of high-density lipoprotein (HDL) cholesterol via cholesteryl ester transfer protein 
inhibitors or apolipoprotein A-1 (ApoA-1) inducers and improving their quality with HDL 
or ApoA-1 mimetics represent also important options. Drugs affecting HDL, however, may 
not be all alike and require adequate scrutiny of the mechanisms involved. Until we have a 
better understanding of these issues, further LDL lowering in high-risk patients represents the 
soundest approach.
Keywords: apolipoproteins, lipids, lipoprotein classes, hypercholesterolemia, synthesis, LDL 
lowering
Introduction
The discovery of statins provided a very effective approach in reducing cardiovascular 
risk, as documented by the results obtained in clinical trials and in clinical practice. 
This class of drugs inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) 
reductase activity, thus halting the conversion of acetyl coenzyme A and acetoacetyl 
coenzyme A to mevalonate, a key step in cholesterol synthesis. This inhibition leads to 
a reduced synthesis of cholesterol in the liver and in an increased expression of hepatic 
low-density lipoprotein receptor (LDL-R). The latter is responsible for increased LDL 
cholesterol (LDL-C) and reduced plasma levels of LDL-C and other apolipoprotein 
(apo)B-containing lipoproteins including microsomal triglyceride-rich particles.
Despite the efficacy and the widespread availability of statins in reducing LDL-C 
and cardiovascular risk; the proportion of patients who fail to achieve their lipid 
targets ranges from 16% to 53%, worldwide. Additionally, many patients are unable 
to tolerate statins, particularly at the highest approved dose level. Finally, up to ∼80% 
of patients with severe forms of this disorder, such as familial hypercholesterolemia 
(FH), are unable to achieve their target levels using conventional therapies, such as 
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statins. Although this gap is partially filled when statins are 
combined to other agents, such as ezetimibe, new treatments 
that aggressively reduce lipid levels in patients with severe 
hypercholesterolemia, or those unable to reach their lipid 
targets, are still required.
In addition, experimental data clearly suggest that 
other lipoprotein classes beyond LDL play important roles 
in determining cardiovascular risk. For these reasons, 
a number of new drugs are under development in this area. 
The aim of this review is to discuss the available and the 
future pharmacological strategies for the management of 
dyslipidemia, including low levels of high-density lipoprotein 
(HDL) cholesterol. Emerging approaches aimed at reducing 
elevated levels of plasma triglycerides and lipoprotein(a) 
were recently presented elsewhere1,2 and will not be 
discussed here.
Current developments 
for lowering LDL
Interfering with lipoprotein synthesis: 
apoB silencing, MTP inhibitors
Hepatic biosynthesis of very low-density lipoprotein 
(VLDL) is dependent on two dominant proteins, namely 
apolipoprotein B (apoB) and microsomal triglyceride (TG) 
transfer protein (MTP). ApoB is an obligatory structural 
component of VLDL and requires progressive lipidation, 
mediated by the resident endoplasmic reticulum chaperone 
MTP, to maintain conformational integrity and folding 
during the process of lipoprotein assembly. Interfering with 
this process is therefore an attractive approach for reducing 
lipoprotein synthesis and decreasing plasma VLDL-C and 
LDL-C concentration. The possibility of targeting apoB 
during the process of gene translation is under extensive 
investigation. One approach to block messenger ribonucleic 
acid (mRNA) translation of a gene is by using a single-strand 
antisense oligonucleotide (ASO) that is complementary to 
the mRNA. Following hybridization to the mRNA, the ASO 
inhibits translation and splicing and leads to degradation 
of the mRNA by ribonuclease (RNase).3 ASO kinetics 
are characterized by a large and rapid distribution to the 
liver following parenteral administration, thus making 
this approach quite attractive for inhibiting mRNA post-
transcriptional processing.1,2 This results in a reduced 
synthesis of proteins in the liver, such as apoB4 (Figure 1). 
Preclinical studies demonstrated that ASOs targeting 
apoB are quite effective in mice in reducing apoB mRNA 
liver levels in a dose–response manner,5 followed by a 
reduction in circulating LDL-C concentration, LDL particle 
number, circulating TG, and lipoprotein(a) (Lp[a]), while 
chylomicrons, which contain apoB-48, were spared, because 
of the high distribution of ASOs to the liver.
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Figure 1 Emerging targets and agents for LDL-cholesterol lowering.
Notes: Emerging therapeutic agents for LDL-C lowering have been designed: (a) to reduce apoB containing lipoprotein synthesis in the liver; or (b) to improve LDL 
catabolism. Mipomersen silences apoB expression while lomitapide inhibits MTP activity. Blocking PCSK9 activity by monoclonal antibodies, or through gene silencing 
promotes LDL-R activity.
Abbreviations: LDL, low-density lipoprotein; LDL-C, low-density lipoprotein catabolism; apoB, apolipoprotein B; MTP, microsomal triglyceride transfer protein; 
PCSK9, proprotein convertase subtilisin/kexin type 9; mRNA, messenger RNA; LDL-R, LDL-receptor; vLDL, very low-density lipoprotein; ab, antibody.
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Mipomersen is an ASO-targeting apoB which leads to 
a dose-dependent reduction in apoB and total cholesterol.6 
This approach was effective in Phase II and Phase III 
clinical studies, in combination with statin therapy with 
or without ezetimibe, bile acid sequestrant, and/or niacin. 
The treatment was effective also in patients with FH,6 
as well as in monotherapy in individuals with mild to 
moderate hyperlipidemia7 and in high-risk statin-intolerant 
patients.8 Overall, mipomersen provided significant further 
reduction in LDL-C (∼30%) and other lipids when added 
to conventional lipid therapy. The most common adverse 
effects were injection-site reactions and flu-like symptoms. 
Liver fat accumulation was also observed in both Phase II 
and Phase III studies and is in line with the mechanism of 
action of the drug.2 As of January 2013, mipomersen has been 
approved by the US Food and Drug Administration (FDA) 
for use in homozygous FH with a warning for the possible 
clinical consequences of the liver fat accumulation (http://
www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/
ucm337195.htm). The European Medicines Agency 
Committee for Medicinal Products for Human Use, however, 
issued a negative opinion on mipomersen based on safety 
issues, and further assessment is awaited.
MTP, found in the endoplasmic reticulum of hepatocytes 
and enterocytes, mediates the formation of apoB-contain-
ing lipoproteins in the liver and in the intestine.9 Mutations 
in the gene encoding MTP can cause abetalipoproteine-
mia, a rare genetic disease characterized by an absence 
of apoB-containing lipoproteins and severe malabsorp-
tion of fat and fat-soluble vitamins.9 The genetic defect 
underlying abetalipoproteinemia suggests that inhibiting 
MTP may reduce circulating concentrations of cholesterol 
and apoB-containing lipoproteins (Figure 1). The MTP 
inhibitor lomitapide is currently in Phase III testing. The 
drug, tested in monotherapy or in combination with con-
ventional lipid-lowering therapy in homozygous FH10 or 
in patients with hypercholesterolemia (LDL-C 130 mg/
dL–250 mg/dL),11 showed a reduction in circulating LDL-
C, apoB, total cholesterol, non-high-density lipoprotein 
cholesterol (non-HDL-C) and Lp(a) levels. Steatorrhea 
related to lomitapide treatment was effectively reduced 
by a fat-restricted diet; adverse effects, such as elevated 
liver enzymes and hepatic fat accumulation (expected from 
the mechanism of action), were reported and may restrict 
the patient population for this drug. However, for patients 
with homozygous FH that cannot be controlled with con-
ventional lipid-lowering therapy, MTP inhibition may be 
a beneficial approach.
In December 2012, lomitapide was approved by the US 
FDA for the treatment of patients with homozygous FH. To 
date, no cases of suspected drug-induced liver injury have 
been observed in lomitapide-treated subjects. As the liver 
lipid accumulation may vary greatly from patient to patient, 
this matter requires careful consideration and longer term 
follow-up to exclude specific changes leading to fibrosis 
and cirrhosis, especially in the light of the very low-fat diet 
that the FH patients were adhering to and the low-fat liver 
content at baseline.
Promoting LDL-receptor activity: 
PCSK9 inhibitors
Cholesterol homeostasis is regulated by the LDL-R through 
its binding and uptake of circulating apoB-containing 
lipoproteins which are then internalized into the liver cell. 
The key mechanism associated with statins’ action involves 
the increase of LDL-R expression on the hepatocyte surface, 
followed by increased LDL turnover and reduction of plasma 
cholesterol levels. This mechanism is partially dampened by 
a negative feedback response associated with the induction 
of the expression and secretion of proprotein convertase 
subtilisin/kexin type 9 (PCSK9),12 a serine protease which 
promotes the degradation of LDL-R,13 thus attenuating, 
at least in part, the lipid-lowering eff icacy of statins 
and ezetimibe.14 More recently it was suggested that, in 
hepatocytes, PCSK9 directly interacts with apoB and reduces 
its intracellular degradation, resulting in increased apoB 
output independently of the LDL-R.15 The PCSK9/apoB 
interaction inhibits intracellular degradation of apoB via the 
autophagosome/lysosome pathway, and this, in turn, results 
in increased secretion of apoB-containing lipoproteins 
and increased levels of cholesterol and triacylglycerol 
(TAG).15
Given that PCSK9 acts both intracellularly, as a 
chaperone directing the LDL-R to the lysosomes or 
promoting apoB secretion, and in the circulation, by 
promoting LDL-R internalization,14 the possibility of 
inhibiting PCSK9 represents a logical step to enhance the 
lipid-lowering effect of conventional agents14 (Figure 1). To 
this end, at least five different human monoclonal antibodies 
and three gene-silencing approaches are under development. 
Among a series of antibodies against PCSK9, clinical 
trial results are available for two of them, SAR236553/
REGN72716 and AMG 145,17 and these compounds are 
both in Phase II or Phase III development. A number of 
additional anti-PCSK9 monoclonal antibodies, in earlier 
clinical development, are currently being investigated for 
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potential use in humans, including 1B20, PF-04950615/
RN-316, and LGT 209.2
To date the largest body of information is available 
for REGN727/SAR236553, a fully human monoclonal 
antibody, which binds to the catalytic domain of PCSK9 
that interacts with LDL-R. Overall, results from Phase I and 
Phase II clinical trials suggest that subcutaneous injections 
of SAR236553/REGN727 dose dependently reduce PCSK9 
activity and produce significant additional reductions in 
LDL-C, as well as in non-HDL-C independently of statin 
treatment. The antibody was generally well-tolerated over 
the treatment period, with no drug-related adverse effects on 
liver function tests or other laboratory parameters, and no 
serious treatment-emergent adverse effects.16,18,19 The number 
of injection-site reactions (including erythema, pruritus, 
swelling, hematoma, and rash) was generally low, and the 
few reported were mild in severity.18
AMG 145 is another fully human monoclonal antibody 
which also binds specifically to human PCSK9. Phase I data 
in subjects on stable statin therapy demonstrated a dose-
dependent decrease in LDL-C and unbound PCSK9 with 
increasing subcutaneous doses of AMG 145. LDL-C was 
lowered by up to 81% at maximal doses, over and above the 
LDL lowering achieved with statin alone.17 Phase I data17 
indicated no serious adverse events in the AMG 145 group, 
compared with placebo, no discontinuations from the studies 
related to adverse events, and only one case of transaminase 
elevation .3× the upper limit of normal. Although the safety 
results for PCSK9 monoclonal antibodies are encouraging, 
it should be noted that the trials to date have been relatively 
short in duration and were conducted in relatively small 
patient populations. Further trials are therefore required to 
test the long-term safety and efficacy of PCSK9 monoclonal 
antibodies in larger and more varied patient populations. In 
this context, given that statin treatment increases PCSK9 
levels, it should be considered that the frequency of injection 
may be increased accordingly in statin-treated patients for 
optimal PCSK9 inhibition.
PCSK9 can also be suppressed through gene silencing 
with the nucleic acid–based therapies.1 Among them, the 
development of SPC5001, a locked nucleic acid-based 
inhibitor, and that of BMS-844421, an antisense RNA 
therapy, were terminated during Phase I clinical trials. ALN-
PCS02, an RNA interference molecule, is being tested in 
an ongoing Phase I study in healthy volunteers to evaluate 
safety and tolerability of various doses. In interim data on 
20 subjects, robust target protein knockdown was observed 
at the highest dose tested, with a mean 60% reduction in 
plasma PCSK9 levels 3–5 days after administration. In 
line with PCSK9 genetics, this type of knockdown entailed 
a mean 39% reduction in LDL-C, with no drug-related 
discontinuations or liver enzyme elevations.19
A new class of agents, the cholesteryl ester transfer 
protein (CETP) inhibitors (see the Emerging approaches 
for increasing HDL paragraph), which were developed on 
the premise that they would increase HDL-C more than any 
therapy currently available, are currently emerging as agents 
able to relevantly reduce LDL-C. Anacetrapib at 100 mg/day 
in patients with coronary heart disease or risk equivalent 
conditions (peripheral artery disease, cerebrovascular disease, 
diabetes, or a 10-year Framingham Risk Score .20%) 
reduced LDL-C by 40% with no changes in blood pressure 
or serum aldosterone levels.21,22 In a Phase II study, 
evacetrapib (30 mg, 100 mg, or 500 mg daily) increased 
HDL-C levels (+53.6% to +128.8%) and reduced LDL-C 
(−13.6% to −35.9%) compared to placebo. Evacetrapib 
100 mg daily in combination with statins increased 
HDL-C levels by 80% and decreased LDL-C levels by 
12% above statin monotherapy.23 The possibility that, for 
CETP inhibitors, the benefit may still be largely due to the 
incremental lowering of LDL-C observed with the more 
potent inhibitors, should be considered for the transfer of 
these drugs in the clinical practice.
Emerging approaches 
for increasing HDL
Increasing plasma HDL-C levels: 
CETP inhibitors, apoA-I inducers
HDLs possess several physiological activities that may 
explain their antiatherosclerotic properties. Among them, 
the most relevant is the ability of HDL to promote the 
efflux of excess cholesterol from peripheral tissues to the 
liver for excretion.24,25 Is this context, reverse cholesterol 
transport from macrophages in the atherosclerotic lesions 
was suggested to influence atherosclerosis by limiting 
foam cells formation.24,25 Of note, the HDL also traffics 
cholesterol to the gut (the transintestinal cholesterol 
efflux), adipocytes, and steroidogenic tissues and could 
also exchange cholesterol esters with apoB containing 
lipoproteins. Furthermore, apolipoproteins, lipids, 
and enzymes carried by HDL may perform additional 
antiatherosclerotic activities.26–30
In recent years, the metabolic pathways associated with 
HDL have been extensively investigated and elucidated, 
allowing the design of drugs able to interfere with HDL 
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catabolism, improve the expression of the main protein 
constituent, namely apoA-I, or mimic their activity.
The pharmacological approaches under development 
can be grouped in two major clusters – molecules increasing 
plasma HDL levels and molecules improving HDL function. 
It is expected that an increase in HDL levels can be beneficial 
when associated with an improvement in HDL function.
Recently, a Mendelian randomization analysis revealed 
that a single nucleotide polymorphism in the endothelial 
lipase gene (LIPG Asn396Ser) associated with increased 
HDL-C levels in the population did not decrease the risk 
of myocardial infarction, despite a 13% reduction expected 
from the increased HDL-C levels.31 Similarly, a genetic 
score combining 14 variants exclusively related to HDL-C 
was not associated with myocardial infarction risk,31 further 
challenging the concept that higher HDL-C levels will 
automatically translate into lower cardiovascular risk. In 
spite of these observations, clinical trials are still ongoing 
with drugs affecting HDL levels.
Cholesteryl ester transfer protein (CETP) is an enzyme 
involved in the transfer of cholesteryl esters from HDL to 
LDL and VLDL. This process results in a reduction and 
remodeling of HDL particles and in an increase of LDL and 
VLDL levels. Furthermore, CETP transfers TG from VLDL 
or LDL to HDL, resulting in the formation of TG-enriched 
HDL, which is easily hydrolyzed by hepatic lipase, leading 
to TG-rich small HDL that are cleared more rapidly from 
the circulation.32 Under pathological conditions, including 
atherosclerosis, CETP activity is increased; moreover, in 
humans, CETP deficiency results in increased HDL levels. 
Altogether, these observations led to the concept that CETP 
inhibition is a powerful tool to increase HDL-C, decrease 
LDL-C and VLDL-C, and reduce the development of 
atherosclerosis.33
The f irst CETP inhibitor developed, torcetrapib, 
despite a 72% increase in HDL-C levels, was withdrawn 
because of an increased risk of cardiovascular events and 
death from any cause in the Investigation of Lipid Level 
Management to Understand its Impact in Atherosclerotic 
Events (ILLUMINATE) trial.34 Retrospectively, this 
effect was attributed to an off-target effect of torcetrapib, 
such as the rising of systolic blood pressure by an average 
5.4 mmHg,35 an effect associated with the stimulation of 
aldosterone synthesis, via pathways independent of CETP 
inhibition.34,36 The possibility that CETP inhibition per 
se could generate larger cholesterol-enriched HDL with 
impaired cholesterol efflux potential was also proposed.35 
However, this was not confirmed by in vitro studies. Among 
the three newer compounds, dalcetrapib, anacetrapib, and 
evacetrapib, with different potency toward CETP inhibition 
(evacetrapib . anacetrapib . dalcetrapib) and apparently 
lacking the off-target effects of torcetrapib, two remain under 
development, while that of dalcetrapib was recently halted.
The decision to stop dalcetrapib was based on the 
dal-OUTCOMES trial interim analysis, which showed that 
dalcetrapib, in acute coronary syndrome patients, failed 
to demonstrate a significant reduction in cardiovascular 
adverse events.37 In contrast to the earlier CETP inhibitor, 
torcetrapib, no safety concerns were reported. In addition, the 
dal-VESSEL study showed that dalcetrapib reduced CETP 
activity and increased HDL-C levels without affecting nitric 
oxide–dependent endothelial function, blood pressure, or 
markers of inflammation and oxidative stress,38 while the 
dal-PLAQUE study demonstrated some beneficial vascular 
effects of the drug, including the reduction in total vessel 
enlargement over 24 months.39
While disappointing, the pursuit of an extensive program 
of clinical trials and basic research to develop dalcetrapib has 
provided new information on the biology of HDL in both 
man and animal models, and on CETP inhibition as a viable 
therapeutic target for raising levels of HDL-C. Several other 
CETP inhibitors that raise HDL-C levels to a greater extent 
than dalcetrapib and also significantly lower LDL-C and 
other novel HDL-raising agents remain under development. 
Ultimately, the benefits of each of these novel CETP inhibi-
tors must be determined through prospective, randomized, 
clinical outcome trials.
The life cycle of HDL starts from lipid-poor apoA-I, 
termed “nascent” or preβ- HDL (the latter based on the 
characteristic electrophoretic mobility), which promotes 
cholesterol mobilization from the cell membrane mainly 
through the activation of ATP-binding cassette subfamily A 
member 1 protein (ABCA-1). Preβ-HDL accumulates effluxed 
cholesterol and matures to α-HDL, which further promotes 
cholesterol efflux via the activation of different transporters, 
including ABCG-1 and scavenger receptor class B member 1 
(SR-BI) (Figure 1). Induction of the expression of apoA-I is, 
therefore, a cornerstone mechanism of drugs so far used to 
increase HDL levels, including fibrates and nicotinic acid.40 
A novel, small synthetic molecule, RVX-208, is able to induce 
apoA-I synthesis and is under development. Preclinical 
studies in nonhuman primates showed the ability of this 
compound to increase plasma apoA-I and HDL-C levels by 
up to 60% and 97%, respectively. In humans, Asymptomatic 
atrial fibrillation and Stroke Evaluation in pacemaker patients 
and the atrial fibrillation Reduction atrial pacing Trial (the 
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ASSERT study) showed that the administration of RVX-208 
at a dose of 50 mg, 100 mg, or 150 mg twice daily for 12 
weeks resulted in increases in apoA-I (up to 5.6%), HDL-C 
(by 3.2% to 8.3%), and large HDL particles (by 11.1% 
to 21.1%), although the primary endpoint of individual 
pairwise comparisons of apoA-I changes with placebo was 
not statistically significant.41 These findings, although not 
at the level expected, require further evaluation, perhaps 
through the investigation of HDL functionality. Furthermore, 
a clear demonstration that therapies aimed at increasing HDL 
levels are associated with reduced atherosclerotic events is 
warranted.
Improving HDL activity
The rationale behind the development of HDL mimetics is the 
possibility of mimicking the first phase of the HDL life cycle 
and promoting cholesterol efflux, mainly from cholesterol-
loaded cells in the vascular wall, such as macrophages and 
foam cells.
To this aim, lipid-poor apoA-I–phospholipid complexes 
have been extensively studied in preclinical models and 
preliminary studies in humans. So far, different approaches 
are under investigation. CSL-111 is a complex of native 
apoA-I and phosphatidylcholine isolated from soybeans 
which induced a significant reduction in atheroma volume 
compared with baseline.42 The same study showed 
significantly reduced progression of coronary atherosclerosis 
in the CSL-111-treated group compared to the placebo. 
Treatment with CSL-111, however, induced reversible 
alanine aminotransferase elevations exceeding ten times 
the normal upper limit in one-third of patients receiving 
80 mg of the compound, while no changes were observed in 
patients receiving 40 mg/kg.42 To overcome this limitation, 
a reformulated version, CSL-112, with greater cholesterol 
efflux capacity and less hepatotoxicity, is in Phase I study.
A similar approach was tested also by incorporating 
recombinant apoA-I Milano, which differs from normal 
apoA-I by a cysteine-to-arginine substitution at amino 
acid 173. ETC-216 is a complex of apoA-I Milano with 
phospholipid and in a small clinical study significantly 
reduced total atheroma volume, measured by intravascular 
ultrasound, in patients with acute coronary syndrome.43 Since 
2003, ETC-216 development was halted and, only recently, 
a different company bought the license and renamed the 
molecule “MDCO-216,” with the aim of starting larger 
clinical trials soon.
CER-001, a synthetic recombinant human apoA-I HDL 
mimetic, is being tested in approximately 500 patients 
with acute coronary syndrome to determine the effect on 
atherosclerotic plaque progression/regression as assessed 
by intravascular ultrasound (Chi square).44 Several other 
complexes of apoA-I and different phospholipids are in 
preclinical development and will soon enter clinical testing 
phases. Also, micro RNA were proposed to influence the 
expression of key genes involved in the HDL life cycle and 
cholesterol efflux.45 Micro RNA-33 represents an interesting 
target, but further studies are required.
A second approach to improve HDL function is 
represented by small peptides designed to mimic apoA-I 
function. The most well-studied of these peptides is 4F, 
consisting of 18 amino acids, which was designed to have 
the lipid-binding properties of apoA-I through a common 
secondary structure, the class A amphipathic helix. The 
use of D-amino acids (D-4F) enables oral delivery of this 
compound by conferring resistance to gastrointestinal 
proteolytic enzymes. Several preclinical studies showed 
that 4F promotes cholesterol efflux via ABCA1 and SR-BI 
and possesses anti-inflammatory, antithrombotic, and 
antioxidant properties. The only available human study of 
D-4F showed that HDL isolated from subjects treated with 
a single 300 mg or 500 mg dose of unformulated D-4F had 
increased inhibition of LDL-induced monocyte chemotaxis, 
compared to HDL isolated from control subjects. Data on 
the safety profile of D-4F in humans are not available yet. 
Overall at least 22 apoA-I mimetics are under development;46 
however, with the exception of D-4F, the other peptides 
require parenteral administration and, in humans, data on 
efficacy, tolerability, and safety, including autoantibody 
generation, are lacking.
Table 1 New targets and agents in cholesterol control 
Target Pharmacological 
approach
Drug
LDL lowering
Apolipoprotein B Gene silencing Mipomersen
MTP Inhibitors Lomitapide
PCSK9 Monoclonal 
antibodies
SAR236553/REGN727 
AMG 145
HDL increase
CETP Inhibitors Anacetrapib 
Evacetrapib
ApoA-I Inducers RvX-208
ApoA-I/HDL Mimetics CSL-111 
ETC-216 
CER-001 
D-4F
Abbreviations: MTP, microsomal triglyceride transfer protein; PCSK9, proprotein 
convertase subtilisin/kexin type 9; CETP, cholesteryl ester transfer protein; ApoA-I, 
apolipoprotein A-I; HDL, high-density lipoprotein.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
82
Norata
Research Reports in Clinical Cardiology 2013:4
Conclusion
Many patients do not achieve the recommended goals 
despite maximal statin therapy, and some patients 
cannot tolerate high-dose statin therapy. Available agents 
combined with statins can provide additional benefits 
on LDL-C reduction, and agents in development may 
increase therapeutic options. Drugs affecting old players in 
lipoprotein metabolism, such as apoB and MTP, have been 
recently approved for the management of dyslipidemia in 
FH patients (Table 1). Genetic insights into mechanisms 
underlying regulation of LDL-C levels have identified 
PCSK9 as a key target and led to the development of 
novel agents that are still undergoing testing to determine 
eff icacy and safety (Table 1). Drugs increasing HDL 
may not be all alike and require adequate scrutiny of the 
mechanisms involved; increasing apoA-I may represent the 
best approach (Table 1). The most promising approaches, 
such as inhibitors of the synthesis of apoB containing 
lipoproteins or PCSK9 inhibitors, all decrease LDL as well. 
Until we have a better understanding of these issues, further 
LDL lowering in high-risk and very high-risk individuals 
represents the soundest clinical approach.
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